Allicin‒Decorated FeO 1‐x OH Nanocatalytic Medicine for Fe 2+ /Fe 3+ Cycling‒Promoted Efficient and Sustained Tumor Regression
Advanced Science · 2024
DOI: 10.1002/advs.202402801 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Zhongming Jie und 2 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Tenth People's Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, School of Medicine, Tongji University, Shanghai, 20007…. Hauptthemen laut MEDLINE: Disulfides, Sulfinic Acids. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research Program of Frontier Sciences, Chinese Academy of Sciences, Basic Research Program of Shanghai Municipal Government, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
In the tumor treatment by Fenton reaction‒based nanocatalytic medicines, the gradual consumption of Fe(II) ions greatly reduces the production of hydroxyl radicals, one of the most active reactive oxygen species (ROS), leading to much deteriorated therapeutic efficacy. Meanwhile, the ROS consumption caused by the highly expressed reduced glutathione (GSH) in the tumor microenvironment further prevents tumor apoptosis. Therefore, using the highly expressed GSH in tumor tissue to promote the Fe(III) reduction to Fe(II) can not only weaken the resistance of tumor to ROS attack, but also generate enough Fe(II) to accelerate the Fenton reaction. In view of this, an allicin‒modified FeO 1‐x OH nanocatalyst possessing varied valence states (II, III) has been designed and synthesized. The coexistence of Fe(II)/Fe(III) enables the simultaneous occurrence of Fenton reaction and GSH oxidation, and the Fe(III) reduction by GSH oxidation results in the promoted cyclic conversion of Fe ions in tumor and positive catalytic therapeutic effects. Moreover, allicin capable of regulating cell cycle and suppressing tumor growth is loaded on FeO 1‐x OH nanosheets to activate immune response against tumors and inhibit tumor recurrence, finally achieving the tumor regression efficiently and sustainably. This therapeutic strategy provides an innovative approach to formulate efficient antitumor nanomedicine for enhanced tumor treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Tenth People's Hospital, Shanghai Frontiers Science Center of Nanocatalytic Medicine, School of Medicine, Tongji University, Shanghai, 200072, P. R. China.
- School of Physical Science and Technology, ShanghaiTech University, Shanghai, 201210, P. R. China.
- Shanghai Institute of Ceramics, Chinese Academy of Sciences, Research Unit of Nanocatalytic Medicine in Specific Therapy for Serious Disease, Chinese Academy of Medical Sciences (2021RU012), Shanghai, 200050, P. R. Chin…
- Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing, 100049, P. R. China.
ORCID-Profile: Bingyan Xiong, Jianlin Shi
Förderung
- Key Research Program of Frontier Sciences, Chinese Academy of Sciences
- Basic Research Program of Shanghai Municipal Government
- Fundamental Research Funds for the Central Universities
- National Key Research and Development Program of China
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China
- CAMS Innovation Fund for Medical Sciences
Zitieren
APA
Jie, Z., Xiong, B., & Shi, J. (2024). Allicin‒Decorated FeO 1‐x OH Nanocatalytic Medicine for Fe 2+ /Fe 3+ Cycling‒Promoted Efficient and Sustained Tumor Regression. Advanced Science. https://doi.org/10.1002/advs.202402801
Vancouver
Jie Z, Xiong B, Shi J. Allicin‒Decorated FeO 1‐x OH Nanocatalytic Medicine for Fe 2+ /Fe 3+ Cycling‒Promoted Efficient and Sustained Tumor Regression. Advanced Science. 2024. doi:10.1002/advs.202402801
BibTeX
@article{Jie2024,
author = {Jie, Zhongming and Xiong, Bingyan and Shi, Jianlin},
title = {Allicin‒Decorated FeO 1‐x OH Nanocatalytic Medicine for Fe 2+ /Fe 3+ Cycling‒Promoted Efficient and Sustained Tumor Regression},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202402801}
}
EUVIMED